

I hereby certify that this correspondence is being facsimile
transmitted to the United States Patent and Trademark Office,
Fax No. 1-703-872-9307 on 9/26/02

PATENT
Attorney Docket No.: 15270J-004741US
Client Ref. No.: 209-US-CIP5C1

TOWNSEND and TOWNSEND and CROW LLP

By: 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dale B. Schenk

Application No.: 09/723,713

Filed: November 27, 2000

For: PREVENTION AND TREATMENT
OF AMYLOIDOGENIC DISEASE

Examiner: Sharon Turner

Art Unit: 1647

AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper is being submitted in response to the Office Action mailed March 26, 2002. A petition to extend the time to respond for three months, from June 26, 2002 to September 26, 2002 is submitted herewith. Please amend the above-identified application as follows.

IN THE SPECIFICATION:

Please replace the paragraph beginning at line 25 of page 14 with the following replacement paragraph.

C¹
Polyclonal sera typically contain mixed populations of antibodies binding to several epitopes along the length of A β . Monoclonal antibodies bind to a specific epitope within A β that can be a conformational or nonconformational epitope. Some monoclonal antibodies bind to an epitope within residues 1-28 of A β (with the first N terminal residue of natural A β designated 1). Some monoclonal antibodies bind to an epitope with residues 1-10 of A β . Some monoclonal antibodies bind to an epitope with residues 1-16 of A β . Some monoclonal

12/c
M.G.J.
9/28/02